Equities

LeMaitre Vascular Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

LeMaitre Vascular Inc

Actions
  • Price (EUR)73.50
  • Today's Change1.50 / 2.08%
  • Shares traded102.00
  • 1 Year change-22.22%
  • Beta0.7032
Data delayed at least 15 minutes, as of Feb 11 2026 07:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.

  • Revenue in USD (TTM)240.87m
  • Net income in USD53.34m
  • Incorporated1998
  • Employees651.00
  • Location
    LeMaitre Vascular Inc63 2nd AveBURLINGTON 01803United StatesUSA
  • Phone+1 (781) 221-2266
  • Fax+1 (302) 636-5454
  • Websitehttps://www.lemaitre.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.